As I See It
A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive
FDA has insisted that its antique regulations can address every new promotional challenge
The more clarity that FDA provides, the more confident companies can be in their medical communications
We need for pharmaceutical companies to come forward and make the pledge to stop hiding data
FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals
It's fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes
Keeping up with quality programs often feels like a safari in a jungle of government paperwork
Could PAG change the FDA inspection paradigm from honest, objective assessments to faster, easier ones?
By opposing making clinical trial data public, Pharma is once again swimming against the current
CMS recognized that the rules in place for CME provide for separation from supporter influence
The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.